EIGR - セラドン （Eiger BioPharmaceuticals Inc.） セラドンEIGRのチャート
EIGRの企業情報
| symbol | EIGR |
|---|---|
| 会社名 | Eiger BioPharmaceuticals Inc （セラドン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Eiger BioPharmaceuticals Inc. formerly Celladon Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV) exendin (9-39) for severe hypoglycemia and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara Turkey) LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema. セラドンは心臓血管疾患の遺伝子治療の開発に焦点を置く米国のバイオ医薬品会社。筋小胞体カルシウムATPア―ゼ（SERCA2：細胞内のカルシウムを制御する酵素)をタ―ゲットした心不全の治療薬「MYDICAR」の治験を行う。また、糖尿病や神経変性疾患に対するSERCA2の開発を行う。 Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. |
| 本社所在地 | 2155 Park Boulevard Palo Alto CA 94306 USA |
| 代表者氏名 | David A Cory デビッド・ア・コーリー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-279-9845 |
| 設立年月日 | 36861 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 16人 |
| url | www.celladon.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eigr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -37.52800 |
| 終値（lastsale） | 11.2 |
| 時価総額（marketcap） | 159535846.4 |
| 時価総額 | 時価総額（百万ドル） 158.39630 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 105.17830 |
| 当期純利益 | 当期純利益（百万ドル） -38.80900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Eiger Biopharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $18.7M. Lower net loss reflects Research and development - Balancing val decrease of 27% to $11.1M (expense) Stock-based Compensation in SGA decrease of 14% to $1.5M (expense) Interest Income increase of 27% to $283K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.68 to -$1.66. |
EIGRのテクニカル分析
EIGRのニュース
As The Stock Rises By 39.69% Year-To-Date, Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR)’S Stock Continues To Progress In 2022 2022/09/17 12:30:00 Marketing Sentinel
During the last session, Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)’s traded shares were 0.46 million, with the beta value of the company hitting 1.66. At the end of the trading day, the stock’s price was $7.25, reflecting an intraday loss of -3.97% or -$0.3. The 52-week high for the EIGR share is $10.02, that puts it down … As The Stock Rises By 39.69% Year-To-Date, Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR)’S Stock Continues To Progress In 2022 Read More »
Eiger BioPharma PT Lowered to $48 at BTIG 2022/09/07 11:03:01 Investing.com
https://www.investing.com/news/pro/eiger-biopharma-pt-lowered-to-48-at-btig-432SI-2887374
IVERIC, First Wave top healthcare gainers; Eiger, bioAffinity lead losers'' pack 2022/09/06 14:07:04 Seeking Alpha
IVERIC bio ISEE +37%. First Wave BioPharma (FWBI) +32%. Eiger BioPharmaceuticals EIGR -29%. bioAffinity Technologies (BIAF) -22%.
EIGR stock falls amid uncertainty over FDA nod for COVID-19 therapy (NASDAQ:EIGR) 2022/09/06 13:28:41 Seeking Alpha
The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc
Eiger BioPharmaceuticals Earnings Perspective: Return On Capital Employed 2022/08/24 14:02:24 Benzinga
According to Benzinga Pro data, during Q2, Eiger BioPharmaceuticals (NASDAQ: EIGR ) posted sales of $4.09 million. Earnings were up 3.35%, but Eiger BioPharmaceuticals still reported an overall loss of $21.88 million. In Q1, Eiger BioPharmaceuticals brought in $2.67 million in sales but lost $22.64 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
Eiger BioPharmaceuticals Inc Shares Fall 3.1% Below Previous 52-Week Low - Market Mover 2022/01/14 06:14:08 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed 3.1% lower than its previous 52 week low, giving the company a market cap of $155M. The stock is currently down 11.6% year-to-date, down 59.5% over the past 12 months, and down 60.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 47.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.7% The company's stock price performance over the past 12 months lags the peer average by 295.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Eiger BioPharmaceuticals Inc Shares Close in on 52-Week Low - Market Mover 2022/01/11 01:53:58 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.5% above its 52 week low of $4.78, giving the company a market cap of $165M. The stock is currently down 6.0% year-to-date, down 58.2% over the past 12 months, and down 58.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 43.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -422.9% The company's stock price performance over the past 12 months lags the peer average by 313.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Eiger BioPharmaceuticals Inc Shares Approach 52-Week Low - Market Mover 2022/01/07 02:44:59 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 0.6% above its 52 week low of $4.95, giving the company a market cap of $169M. The stock is currently down 4.0% year-to-date, down 60.4% over the past 12 months, and down 57.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 47.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -332.2% The company's stock price performance over the past 12 months lags the peer average by 399.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Eiger BioPharmaceuticals Inc Shares Near 52-Week Low - Market Mover 2021/12/30 01:30:23 Kwhen Finance
Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.0% above its 52 week low of $5.07, giving the company a market cap of $175M. The stock is currently down 57.9% year-to-date, down 50.1% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 291.2% The company's stock price performance over the past 12 months lags the peer average by 209.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection 2021/12/21 21:05:00 Business Insider Markets
PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious
Caxton Corp Buys Rezolute Inc, Addex Therapeutics, Lux Health Tech Acquisition Corp, Sells ... 2021/08/24 18:38:06 GuruFocus
Related Stocks: GOOG , INTU , PYPL , CDLX , FB , EIGR , RZLT , ADXN , LUXA , FLAC , SSAAU , GIGGU , MRAC , PTMN , GMIIU , FTOC , HEC , VGAC ,
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call Transcript 2021/08/08 13:37:04 Seeking Alpha
thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI 2021/08/07 23:25:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI appeared first on .
Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism 2021/08/05 12:00:00 PR Newswire
PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food
Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences 2021/08/03 20:05:00 PR Newswire
PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory,